Summary
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the physician’s choice to treat platinum-sensitive relapsed ovarian cancer.
Register to download
Embracing a Risk-based Approach
You may also be interested in:
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
View Resource
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…
View Resource
resource
The Future of Clinical Trials: Connected and Virtual Approaches for Rare Diseases
Scott Schliebner, Senior Vice President, Center for Rare Diseases at PRA Health Sciences talks about how amore patient-centred approach is needed to…
View Resource
View all related content and resources for Study Design
Explore Insights